Avadel Pharma (AVDL) Misses Q3 EPS by 3c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.41), $0.03 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $7.01 million versus the consensus estimate of $5.12 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Deutsche Bank monitors UK auto sales as Chinese exports grow
• BMO starts chip stocks coverage: Here are its preferred picks